CEO of MyoGene Bio
MB
MyoGene Bio
This company develops gene-editing therapies to treat Duchenne muscular dystrophy by targeting the underlying genetic cause of the disease. Their technology aims to significantly impact disease progression for patients with this muscle disorder.
- Biotechnology
Updated 5 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- This company develops gene-editing therapies to treat Duchenne muscular dystrophy by targeting the underlying genetic cause of the disease. Their technology aims to significantly impact disease progression for patients with this muscle disorder.